Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study

NCT04619316 is registered in ClinicalTrials.gov with University Hospital, Essen as lead sponsor.

NCT NCT04619316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04619316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study
Lead sponsor
University Hospital, Essen
Phase
Phase 2
Overall status
Unknown status
Start date
February 5, 2018
Completion date
December 31, 2024
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic thyroid cancer